The interaction between prognostic and pharmacodynamic biomarkers

L. Bouranis; M. Sperrin; A. Greystoke; C. Dive; A. G. Renehan

doi:10.1038/bjc.2013.527

The interaction between prognostic and pharmacodynamic biomarkers

L. Bouranis, M. Sperrin, A. Greystoke, C. Dive, A. G. Renehan

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Abstract

Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions. © 2013 Cancer Research UK.

Original language	English
Pages (from-to)	1782-1785
Number of pages	3
Journal	British Journal of Cancer
Volume	109
Issue number	7
DOIs	https://doi.org/10.1038/bjc.2013.527
Publication status	Published - 1 Oct 2013

Keywords

biomarkers
colorectal cancer
pharmacodynamics
prognosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2013.527

Cite this

@article{5bfc513540d14c2f97033c7018f3834a,

title = "The interaction between prognostic and pharmacodynamic biomarkers",

abstract = "Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions. {\textcopyright} 2013 Cancer Research UK.",

keywords = "biomarkers, colorectal cancer, pharmacodynamics, prognosis",

author = "L. Bouranis and M. Sperrin and A. Greystoke and C. Dive and Renehan, {A. G.}",

year = "2013",

month = oct,

day = "1",

doi = "10.1038/bjc.2013.527",

language = "English",

volume = "109",

pages = "1782--1785",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - The interaction between prognostic and pharmacodynamic biomarkers

AU - Bouranis, L.

AU - Sperrin, M.

AU - Greystoke, A.

AU - Dive, C.

AU - Renehan, A. G.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions. © 2013 Cancer Research UK.

AB - Background:Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Methods:Prognostic and PD utilities were assessed with linear mixed-effects models using published data on repeated measurements of circulating caspase-cleaved (ctCK18) and total (tCK18) cytokeratin 18, in 57 patients with metastatic colorectal cancer undergoing chemotherapy.Results:The model for tCK18 (but not cCK18) separated the prognostic/PD interaction from the pure prognostic effect, illustrating the principle of dual prognostic and PD characteristics for a given biomarker.Conclusion:These models provide the framework for the analysis and interpretation of longitudinal data to detect prognostic/PD biomarker interactions. © 2013 Cancer Research UK.

KW - biomarkers

KW - colorectal cancer

KW - pharmacodynamics

KW - prognosis

U2 - 10.1038/bjc.2013.527

DO - 10.1038/bjc.2013.527

M3 - Article

C2 - 24002599

SN - 0007-0920

VL - 109

SP - 1782

EP - 1785

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

The interaction between prognostic and pharmacodynamic biomarkers

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this